Izolo, i-FDA yase-US imemezele ukugunyazwa kwe-antibody-drug conjugate ye-Seattle Genetics' Adcetris (brentuximab vedotin) ehlanganiswe nokwelashwa ngamakhemikhali ezigulini ezinesigaba se-III noma se-IV sakudala se-Hodgkin's lymphoma (cHL). Lokhu kugunyazwa kumelela intuthuko ohlelweni lokuqala lokwelapha lwe-Hodgkin lymphoma ethuthukisiwe eyethulwa ekusebenzeni komtholampilo eminyakeni engaphezu kwengu-40 edlule.
Lymphoma is a type of cancer that begins in the lymphatic system. The immune system helps the body fight infections and diseases. Lymphoma can develop almost anywhere in the body and can spread to nearby lymph nodes. It is divided into two types: IHodgkin lymphoma and non-Hodgkin lymphoma. Most patients with Hodgkin i-lymphoma belong to the classic type. In this type of lymph node, there are large abnormal lymphocytes (a type of white blood cell). Called Reed-Sternberg cells. Through early intervention, patients with Hodgkin’s lymphoma usually get long-term remission.
Ocwaningweni lomtholampilo, amandla e-Adcetris okwelapha i-Hodgkin's lymphoma yaqinisekiswa-abacwaningi baqashe iziguli ezelashwayo eziyi-1,334 ezazithole isilinganiso sezifundo eziyisi-6 zemijikelezo yezinsuku ezingama-28 ngaphambili. Kamuva, bahlukaniswa ngamaqembu amabili, iqembu elilodwa lathola i-Adcetris kanye ne-chemotherapy (AVD), kanti elinye iqembu lathola kuphela i-chemotherapy (ABVD). Ucwaningo luye lwabonisa ukuthi iziguli ezithola ukwelashwa okuhlangene zinengozi ephansi engu-23% yokuqhubeka kwesifo, ukufa, noma isidingo sokuqala ukwelashwa okusha uma kuqhathaniswa neziguli ezithola ukwelashwa ngamakhemikhali kuphela.
Adcetris combines antibodies and drugs, allowing antibodies to direct drugs to amaseli e-lymphoma called CD30, approved for treatment of relapsed classic Hodgkin lymphoma, classic Hodgkin lymphoma with high risk of relapse or progression after stem cell transplantation, accepted Systemic anaplastic large cell lymphoma that other treatments are not effective, and primary cutaneous anaplastic large cell lymphoma that does not work with other treatments.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm
